LEHI, Utah and LOUISVILLE, Ky., Oct. 14, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, announced today that it will report financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. The company will discuss its financial results on a conference call at 4:30 p.m. Eastern Time that same day.
A live audio webcast of the conference call will be available on Waystar's investor relations website at https://investors.waystar.com/news-events/events. The webcast will be archived on the site for those unable to listen in real time.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
502-238-9511

| Last Trade: | US$36.18 |
| Daily Change: | -0.86 -2.32 |
| Daily Volume: | 481,225 |
| Market Cap: | US$6.920B |
October 29, 2025 October 01, 2025 September 10, 2025 September 09, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load